WO2022039551A1 - 피롤로피리딘 유도체 및 이들의 용도 - Google Patents
피롤로피리딘 유도체 및 이들의 용도 Download PDFInfo
- Publication number
- WO2022039551A1 WO2022039551A1 PCT/KR2021/011116 KR2021011116W WO2022039551A1 WO 2022039551 A1 WO2022039551 A1 WO 2022039551A1 KR 2021011116 W KR2021011116 W KR 2021011116W WO 2022039551 A1 WO2022039551 A1 WO 2022039551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- chlorophenyl
- butoxy
- trimethyl
- tert
- Prior art date
Links
- 150000005255 pyrrolopyridines Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- -1 (methoxycarbonyl)oxy Chemical group 0.000 claims description 17
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- FNKMXFDLAVKUSF-DEOSSOPVSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]-N-(2H-tetrazol-5-yl)acetamide Chemical compound CC(C)(C)O[C@H](C(NC1=NNN=N1)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl FNKMXFDLAVKUSF-DEOSSOPVSA-N 0.000 claims description 3
- ZPJPPJQSSBRGGF-DEOSSOPVSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetamide Chemical compound CC(C)(C)O[C@H](C(N)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl ZPJPPJQSSBRGGF-DEOSSOPVSA-N 0.000 claims description 3
- SFVOKUBSHMYDIO-JOCHJYFZSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetonitrile Chemical compound CC(C)(C)O[C@@H](C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl)C#N SFVOKUBSHMYDIO-JOCHJYFZSA-N 0.000 claims description 3
- ABIBIAGJRBRUFF-DEOSSOPVSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-N-hydroxy-2-[(2-methylpropan-2-yl)oxy]acetamide Chemical compound CC(C)(C)O[C@H](C(NO)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl ABIBIAGJRBRUFF-DEOSSOPVSA-N 0.000 claims description 3
- FNWQXOUWRSJFTH-VWLOTQADSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-N-methoxy-2-[(2-methylpropan-2-yl)oxy]acetamide Chemical compound CC(C)(C)O[C@H](C(NOC)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl FNWQXOUWRSJFTH-VWLOTQADSA-N 0.000 claims description 3
- HGYHURYOHXQSQA-SANMLTNESA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-N-methoxy-N-methyl-2-[(2-methylpropan-2-yl)oxy]acetamide Chemical compound CC(C)(C)O[C@H](C(N(C)OC)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl HGYHURYOHXQSQA-SANMLTNESA-N 0.000 claims description 3
- RXFUIFLMGDWFJM-VWLOTQADSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-2-[(2-methylpropan-2-yl)oxy]acetamide Chemical compound CC(C)(C)O[C@H](C(NC)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl RXFUIFLMGDWFJM-VWLOTQADSA-N 0.000 claims description 3
- ISYJMSQBQPKRRW-SANMLTNESA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (2S)-2-[4-(4-chlorophenyl)-1-(2-methoxyethyl)-2,3,6-trimethylpyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetate Chemical compound CC(C)(C)O[C@H](C(OCC(O1)=C(C)OC1=O)=O)C1=C(C)N=C2N(CCOC)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl ISYJMSQBQPKRRW-SANMLTNESA-N 0.000 claims description 3
- RFBLXTDEBKBKLW-PMERELPUSA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (2S)-2-[4-(4-chlorophenyl)-1-[(3,4-difluorophenyl)methyl]-2,3,6-trimethylpyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetate Chemical compound CC(C)(C)O[C@H](C(OCC(O1)=C(C)OC1=O)=O)C1=C(C)N=C2N(CC(C=C3)=CC(F)=C3F)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl RFBLXTDEBKBKLW-PMERELPUSA-N 0.000 claims description 3
- XYYXSEAXLPRCDB-ZUILJJEPSA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-(oxetan-2-ylmethyl)pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetate Chemical compound CC(C)(C)O[C@H](C(OCC(O1)=C(C)OC1=O)=O)C1=C(C)N=C2N(CC3OCC3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl XYYXSEAXLPRCDB-ZUILJJEPSA-N 0.000 claims description 3
- OPWQEJCUCURMIT-NDEPHWFRSA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetate Chemical compound CC(C)(C)O[C@H](C(OCC(O1)=C(C)OC1=O)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl OPWQEJCUCURMIT-NDEPHWFRSA-N 0.000 claims description 3
- ZYWWHYQKCCTWBZ-LJAQVGFWSA-N 2-(2-methoxyethoxy)ethyl (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetate Chemical compound CC(C)(C)O[C@H](C(OCCOCCOC)=O)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl ZYWWHYQKCCTWBZ-LJAQVGFWSA-N 0.000 claims description 3
- PYBOXKSLNAWEFF-DEOSSOPVSA-N 4-(4-chlorophenyl)-2,3,6-trimethyl-5-[(S)-(2-methylpropan-2-yl)oxy-(2H-tetrazol-5-yl)methyl]-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridine Chemical compound CC(C)(C)O[C@H](C1=NN=NN1)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl PYBOXKSLNAWEFF-DEOSSOPVSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- TUOOWAAWTICYLM-QNGWXLTQSA-N tridecyl (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetate Chemical compound CCCCCCCCCCCCCOC([C@H](C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl)OC(C)(C)C)=O TUOOWAAWTICYLM-QNGWXLTQSA-N 0.000 claims description 2
- BUGFFRWMKINMBY-SANMLTNESA-N CC(C)(C)O[C@H](C1=NOC(C)=N1)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl Chemical compound CC(C)(C)O[C@H](C1=NOC(C)=N1)C1=C(C)N=C2N(CC3=CN(C)N=C3)C(C)=C(C)C2=C1C(C=C1)=CC=C1Cl BUGFFRWMKINMBY-SANMLTNESA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 15
- 208000031886 HIV Infections Diseases 0.000 abstract description 4
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 10
- GNRDGAWRAIJOSU-DEOSSOPVSA-N (2S)-2-[4-(4-chlorophenyl)-2,3,6-trimethyl-1-[(1-methylpyrazol-4-yl)methyl]pyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C(C)(C)(C)O[C@H](C(=O)O)C=1C(=C2C(=NC=1C)N(C(=C2C)C)CC=1C=NN(C=1)C)C1=CC=C(C=C1)Cl GNRDGAWRAIJOSU-DEOSSOPVSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- QCLFSYYUWPUWQR-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one Chemical compound CC=1OC(=O)OC=1CCl QCLFSYYUWPUWQR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940124524 integrase inhibitor Drugs 0.000 description 3
- 239000002850 integrase inhibitor Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LVOYCDPTULCEIH-QFIPXVFZSA-N (2s)-2-[4-(4-chlorophenyl)-1-(2-methoxyethyl)-2,3,6-trimethylpyrrolo[2,3-b]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C1=C(C)N=C2N(CCOC)C(C)=C(C)C2=C1C1=CC=C(Cl)C=C1 LVOYCDPTULCEIH-QFIPXVFZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HUXJXNSHCKHFIL-UHFFFAOYSA-N 1-(2-bromoethoxy)-2-methoxyethane Chemical compound COCCOCCBr HUXJXNSHCKHFIL-UHFFFAOYSA-N 0.000 description 1
- BFDNZQUBFCYTIC-UHFFFAOYSA-N 1-bromotridecane Chemical compound CCCCCCCCCCCCCBr BFDNZQUBFCYTIC-UHFFFAOYSA-N 0.000 description 1
- ONZWFHWHTYZZLM-UHFFFAOYSA-N 1-chloroethyl cyclohexyl carbonate Chemical compound CC(Cl)OC(=O)OC1CCCCC1 ONZWFHWHTYZZLM-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 0 B[n]1c2nc(C)c([C@@](*)OC(C)(C)C)c(-c(cc3)ccc3Cl)c2c(C)c1C Chemical compound B[n]1c2nc(C)c([C@@](*)OC(C)(C)C)c(-c(cc3)ccc3Cl)c2c(C)c1C 0.000 description 1
- MDHVNLNBFANHDT-BVHINDKJSA-N CC1=C(N(C2=NC(=C(C(=C12)C3=CC=C(C=C3)Cl)[C@@H](C(=O)O)OC(C)(C)C)C)CC4CCO4)C Chemical compound CC1=C(N(C2=NC(=C(C(=C12)C3=CC=C(C=C3)Cl)[C@@H](C(=O)O)OC(C)(C)C)C)CC4CCO4)C MDHVNLNBFANHDT-BVHINDKJSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- MFSHZGFPADYOTO-UHFFFAOYSA-N chloromethyl methyl carbonate Chemical compound COC(=O)OCCl MFSHZGFPADYOTO-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to antiviral compounds, particularly compounds having high selectivity and physiological activity against human immunodeficiency virus (HIV), and uses thereof.
- HIV human immunodeficiency virus
- AIDS Abquired Immuno Deficiency Syndrome
- HIV-1 HIV-1
- HIV-2 HIV-2
- Enzyme inhibitors have been developed according to the mechanism of action of HIV for the treatment of AIDS. Nucleoside Reverse Transcriptase Inhibitor (NRTI), Protease Inhibitor (PI), Fusion Inhibitors Inhibitors) and integrase inhibitors.
- NRTI Nucleoside Reverse Transcriptase Inhibitor
- PI Protease Inhibitor
- Fusion Inhibitors Inhibitors Fusion Inhibitors Inhibitors
- Integrase inhibitors are divided into catalytic site inhibitory action and non-catalytic site inhibitory action according to their mechanism of action.
- Research on catalytic site integrase inhibitors has been actively conducted so far, and three drugs have been developed and sold on the market.
- Raltegravir, developed in 2008, is a representative drug.
- the mechanism of inhibition of non-catalytic site integrase was introduced by Zeger Debyser et al. (Frauke Christ, Zeger Debyser at al., Nature Chemical Biology, 2010, Vol. 6, 442-448). Development of inhibitors for this mechanism of action This has been actively pursued.
- a pyrrolopyridine derivative compound having a new skeleton has an effect of inhibiting the proliferation of HIV, thereby completing the present invention.
- the present invention provides a pyrrolopyridine derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof having an effect of inhibiting the proliferation of HIV-1 by inhibiting the activity of the integrase enzyme of HIV-1 will be.
- Another object of the present invention is to provide a method for preparing a novel pyrrolopyridine derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a pharmaceutical use of the compound.
- the present invention provides a compound represented by the following formula (I), a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
- R 1 and R 2 are each independently —NR 3 R 4 , —NR 3 OR 4 or —OR 5 ;
- R 3 and R 4 are each independently -hydrogen, -C 1-6 alkyl or -heteroaryl;
- R 5 is -C 5-20 alkyl, -(CH 2 )nO-(CH 2 )-O-CH 3 , -(CH 2 )n-OCOO-CH 3 , -(CH)CH 3 -OCOO-C 3-6 cycloalkyl or -(CH 2 )n-heteroaryl;
- B is -(CH 2 )nR 6 ;
- R 6 is -hydroxy, -amino, -azido, -cyano, -trifluoromethyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 alkoxy, -CONH ( C 1-3 alkyl), -CON(C 1-3 alkyl) 2 , -COOH, -S-(C 1-6 alkyl), -SO 2 -(C 1-6 alkyl), -carbamoyl, -C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, -aryl or -heteroaryl ⁇ wherein one or more of said -C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, -aryl or -heteroaryl H is -C 1-6 alkyl, -C 1-6 haloalkyl, -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl,
- n 1, 2, 3 or 4.
- the compound represented by Formula I, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may be as follows.
- R 1 and R 2 are each independently —NR 3 R 4 , —NR 3 OR 4 or —OR 5 ;
- R 3 and R 4 are each independently -hydrogen, -C 1-6 alkyl or -heteroaryl;
- R 5 is -C 5-20 alkyl, -(CH 2 )nO-(CH 2 )-O-CH 3 , -(CH 2 )n-OCOO-CH 3 , -(CH)CH 3 -OCOO-C 3-6 cycloalkyl or -(CH 2 )n-heteroaryl;
- B is -(CH 2 )nR 6 ;
- R 6 is -C 1-6 alkoxy, 4-6 membered heterocycloalkyl, -C 3-6 cycloalkyl, -aryl or -heteroaryl ⁇ wherein said -C 3-6 cycloalkyl, 4-6 membered hetero at least one H of cycloalkyl, -aryl or -heteroaryl is -C 1-6 alkyl, -C 1-6 haloalkyl, -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl, -C 1 6 may be substituted with alkoxy, -cyano, -carboxy, -amino, -nitro, -azido, -hydroxy, -carbamoyl, -thiol or -halogen ⁇ ;
- n 1, 2 or 3.
- the compound represented by Formula I, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may be as follows.
- R 1 and R 2 are each independently —NR 3 R 4 , —NR 3 OR 4 or —OR 5 ;
- R 3 and R 4 are each independently -hydrogen, -C 1-6 alkyl or -heteroaryl;
- R 5 is -C 5-20 alkyl, -(CH 2 )nO-(CH 2 )-O-CH 3 , -(CH 2 )n-OCOO-CH 3 , -(CH)CH 3 -OCOO-C 3-6 cycloalkyl or -(CH 2 )n-heteroaryl;
- B is -(CH 2 )nR 6 ;
- R 6 is -C 1-6 alkoxy, 4-6 membered heterocycloalkyl, -aryl or -heteroaryl, ⁇ wherein at least one H of said 4-6 membered heterocycloalkyl, -aryl or -heteroaryl is -C 1-6 alkyl, -C 1-6 haloalkyl, -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl, -C 1-6 alkoxy, -cyano, -carboxy, -amino, -nitro, - which may be substituted with -azido, -hydroxy, -carbamoyl, -thiol or -halogen ⁇ ;
- n 1, 2 or 3.
- the compound represented by Formula I, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may be as follows.
- R 1 is -NR 3 R 4 , -NR 3 OR 4 or -OR 5 ;
- R 2 is —NR 3 R 4 ;
- R 3 and R 4 are each independently -hydrogen, -C 1-6 alkyl or -heteroaryl;
- R 5 is -C 5-20 alkyl, -(CH 2 )nO-(CH 2 )-O-CH 3 , -(CH 2 )n-OCOO-CH 3 , -(CH)CH 3 -OCOO-C 3-6 cycloalkyl or -(CH 2 )n-heteroaryl;
- B is -(CH 2 )nR 6 ;
- R 6 is -C 1-6 alkoxy, 4-6 membered heterocycloalkyl, -aryl or -heteroaryl, ⁇ wherein at least one H of said 4-6 membered heterocycloalkyl, -aryl or -heteroaryl is -C may be substituted with 1-6 alkyl or -halogen ⁇ ;
- n 1 or 2.
- the compound represented by Formula I of the present invention may be selected from the group consisting of the following compounds.
- the compounds of formula (I) of the present invention thus prepared are capable of forming salts, in particular pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts are not particularly limited to those commonly used in the art, such as acid addition salts.
- Preferred pharmaceutically acceptable acid addition salts include, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, orthophosphoric acid or sulfuric acid; or organic acids such as, for example, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, acetic acid, propionic acid, lactic acid, citric acid, fumaric acid, malic acid, succinic acid, salicylic acid, maleic acid, glycerophosphoric acid or acetylsalicylic acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, orthophosphoric acid or sulfuric acid
- organic acids such as, for example, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, acetic acid, propionic acid, lactic acid, citric acid, fumaric acid, malic acid, succinic acid, salicylic acid,
- a pharmaceutically acceptable metal salt can be obtained by a conventional method using a base.
- a pharmaceutically acceptable metal salt can be obtained by dissolving the compound of Formula I in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate.
- a salt or solvate of the compound of formula (I) that is not pharmaceutically acceptable may be used as an intermediate in the preparation of the compound of formula (I), a pharmaceutically acceptable salt or solvate thereof.
- the compound of formula (I) of the present invention includes not only pharmaceutically acceptable salts thereof, but also possible solvates and hydrates that can be prepared therefrom. Stereoisomers of the compounds of formula (I) and intermediates can be prepared using conventional methods.
- the compounds of formula (I) according to the invention may be prepared in crystalline or amorphous form, and when the compounds of formula (I) are prepared in crystalline form, they may optionally be hydrated or solvated.
- the present invention provides a pharmaceutical use of the compound of formula (I), a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
- the present invention provides an antiviral pharmaceutical composition comprising the compound of Formula I, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the antiviral composition may be an antihuman immunodeficiency virus (HIV) composition.
- the compound of Formula I has low cytotoxicity and excellent HIV inhibitory effect, and as a bioisostere and prodrug, improves physicochemical properties, improves drug absorption, controls stability and toxicity
- bioisostere and prodrug improves physicochemical properties, improves drug absorption, controls stability and toxicity
- composition of the present invention may be formulated in oral or injection dosage form.
- Formulations for oral administration include, for example, tablets and capsules, and these formulations include, in addition to the active ingredient, diluents (eg, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine), lubricants ( Examples: silica, talc, stearic acid and its magnesium calcium salt or polyethylene glycol).
- diluents eg, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
- lubricants examples: silica, talc, stearic acid and its magnesium calcium salt or polyethylene glycol.
- Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpicolidine, optionally starch, agar, alginic acid or its sodium salt It may contain disintegrants or effervescent mixtures and/or absorbents, colorants, flavoring agents and sweetening agents such as As an injectable formulation, an isotonic aqueous solution or suspension is preferred.
- binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpicolidine, optionally starch, agar, alginic acid or its sodium salt It may contain disintegrants or effervescent mixtures and/or absorbents, colorants, flavoring agents and sweetening agents such as As an injectable formulation, an isotonic aqueous solution or suspension is preferred.
- compositions may be sterilized and/or contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, salts and/or buffers for regulating osmotic pressure, and other therapeutically useful substances.
- adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, salts and/or buffers for regulating osmotic pressure, and other therapeutically useful substances.
- the formulation may be prepared by a conventional mixing, granulating or coating method and may contain the active ingredient in the range of about 0.1 to 75% by weight, preferably about 1 to 50% by weight.
- a unit dosage form for a mammal weighing about 50 to 70 kg contains about 10 to 200 mg of active ingredient.
- the preferred dosage of the compound of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the form of the drug, the route and duration of administration, but may be appropriately selected by those skilled in the art. Administration may be administered once a day or in divided doses via oral or parenteral routes.
- composition of the present invention may be administered to mammals, including rats, mice, livestock, and humans, by various routes. Any mode of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerbroventricular injection.
- the present invention provides a viral infection comprising administration of a therapeutically effective amount of a compound represented by Formula I, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. , in particular a method for preventing or treating HIV infection.
- the present invention also provides a compound represented by the above formula (I), a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable compound thereof for the preparation of a medicament for the treatment of a viral infection, particularly an HIV infection. Possible uses of salts are provided.
- the compound of the present invention a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof has high selectivity and physiological activity and low toxicity against a virus, particularly human immunodeficiency virus (HIV), and thus has low toxicity. It can be usefully used in the treatment of deficiency virus (HIV) infection.
- a virus particularly human immunodeficiency virus (HIV)
- HIV human immunodeficiency virus
- Example 1 tridecyl (S)-2-(tert-butoxy)-2-(4-(4-chlorophenyl)-2,3,6-trimethyl-1-((1-methyl-1H-pyra) zol-4-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)acetate
- Example 5 The compound obtained in Example 5 (100 mg, 0.20 mmol) was dissolved in DCM (0.7 mL), cooled to 0 to 5 °C, triethylamine (31 ⁇ L, 0.61 mmol), TFAA (31 ⁇ L, 0.22 mmol) was added After addition, the mixture was stirred at 0 to 5 °C for 2 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate and aqueous sodium hydrogen carbonate solution, and the organic layer was extracted and washed with purified water. The organic layer was dehydrated over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by column chromatography to obtain the title compound (53 mg) as an off-white solid.
- Example 12 To the compound obtained in Example 12 (325 mg, 0.64 mmol), p-toluenesulfonic acid hydrate (36 mg, 0.19 mmol), zinc chloride (26 mg, 0.19 mmol), and acetonitrile (2.1 mL) were added, and then at 80 °C. Stirred for 3 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with purified water. The organic layer was dehydrated over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by column chromatography to obtain the title compound (9 mg) as an off-white solid.
- Example 17 1-(((cyclohexyloxy)carbonyl)oxy)ethyl (2S)-2-(tert-butoxy)-2-(4-(4-chlorophenyl)-2,3,6 -trimethyl-1-((1-methyl-1H-parazol-4-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)acetate
- step 1 The compound (122 mg, 0.225 mmol) obtained in step 1 was dissolved in a THF:MeOH (1:1) mixture, and then NaOH (27.1 mg, 0.676 mmol) was added thereto, followed by stirring at 40° C. for 13 hours. After the reaction was completed, the reaction solution was diluted with ethyl acetate and washed with purified water. The organic layer was dehydrated over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by column chromatography to obtain the title compound (89.5 mg) as an off-white solid.
- step 2 The compound obtained in step 2 (20 mg, 0.038 mmol) and 4-(chloromethyl)-5-methyl-1,3-dioxol-2-one (9 mg, 0.057 mmol) were prepared in a similar manner to Example 15. to give the title compound (3.1 mg) as a pale yellow solid.
- HIV-1 Wild type of the compound of the present invention
- MT-4 cells were used as host cells, and NL4-3 strain of HIV-1 was used as the virus strain.
- Viruses and cells were mixed in the presence of a compound of the invention and incubated for 6 days.
- Antiviral effect was measured as a percentage reduction in viral cytopathic effect (CPE), and compound cytotoxicity was assessed by dye reduction MTS (CellTiter® 96 Reagent, Promega, Madison WI). The results are shown in Table 1 below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (9)
- 하기 화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염:[화학식 I]상기 식에서,A는 -히드록시, -아미노, -아지도, -시아노, -트리플루오로메틸, -COR1, -C=NOHR2, -B(OH)2, -SO3H, -P=O(OH)2 또는 -헤테로아릴이며;R1 및 R2는 각각 독립적으로 -NR3R4, -NR3OR4 또는 -OR5 이며;R3 및 R4는 각각 독립적으로 -수소, -C1-6 알킬 또는 -헤테로아릴이며;R5는 -C5-20 알킬, -(CH2)n-O-(CH2)-O-CH3, -(CH2)n-OCOO-CH3, -(CH)CH3-OCOO-C3-6 사이클로알킬 또는 -(CH2)n-헤테로아릴이며;B는 -(CH2)n-R6 이며;R6는 -히드록시, -아미노, -아지도, -시아노, -트리플루오로메틸, -C2-6 알케닐, -C2-6 알키닐, -C1-6 알콕시, -CONH(C1-3 알킬), -CON(C1-3 알킬)2, -COOH, -S-(C1-6 알킬), -SO2-(C1-6 알킬), -카바모일, -C3-6 사이클로알킬, 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴이고 {여기서, 상기 -C3-6 사이클로알킬, 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴의 하나 이상의 H는 -C1-6 알킬, -C1-6 할로알킬, -C1-6 아미노알킬, -C1-6 히드록시알킬, -C1-6 알콕시, -시아노, -카르복시, -아미노, -니트로, -아지도, -히드록시, -카바모일, -티올 또는 -할로겐으로 치환될 수 있음};n은 1, 2, 3 또는 4이다.
- 제 1 항에 있어서,A는 -시아노, -COR1, -C=NOHR2, -B(OH)2, -SO3H, -P=O(OH)2 또는 -헤테로아릴이며;R1 및 R2는 각각 독립적으로 -NR3R4, -NR3OR4 또는 -OR5 이며;R3 및 R4는 각각 독립적으로 -수소, -C1-6 알킬 또는 -헤테로아릴이며;R5는 -C5-20 알킬, -(CH2)n-O-(CH2)-O-CH3, -(CH2)n-OCOO-CH3, -(CH)CH3-OCOO-C3-6 사이클로알킬 또는 -(CH2)n-헤테로아릴이며;B는 -(CH2)n-R6 이며;R6는 -C1-6 알콕시, 4-6원 헤테로시클로알킬, -C3-6 사이클로알킬, -아릴 또는 -헤테로아릴이고 {여기서, 상기 -C3-6 사이클로알킬, 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴의 하나 이상의 H는 -C1-6 알킬, -C1-6 할로알킬, -C1-6 아미노알킬, -C1-6 히드록시알킬, -C1-6 알콕시, -시아노, -카르복시, -아미노, -니트로, -아지도, -히드록시, -카바모일, -티올 또는 -할로겐으로 치환될 수 있음};n은 1, 2 또는 3인;화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염.
- 제 1 항에 있어서,A는 -시아노, -COR1, -C=NOHR2 또는 -헤테로아릴이며;R1 및 R2는 각각 독립적으로 -NR3R4, -NR3OR4 또는 -OR5 이며;R3 및 R4는 각각 독립적으로 -수소, -C1-6 알킬 또는 -헤테로아릴이며;R5는 -C5-20 알킬, -(CH2)n-O-(CH2)-O-CH3, -(CH2)n-OCOO-CH3, -(CH)CH3-OCOO-C3-6 사이클로알킬 또는 -(CH2)n-헤테로아릴이며;B는 -(CH2)n-R6 이며;R6는 -C1-6 알콕시, 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴이고 {여기서, 상기 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴의 하나 이상의 H는 -C1-6 알킬, -C1-6 할로알킬, -C1-6 아미노알킬, -C1-6 히드록시알킬, -C1-6 알콕시, -시아노, -카르복시, -아미노, -니트로, -아지도, -히드록시, -카바모일, -티올 또는 -할로겐으로 치환될 수 있음};n은 1, 2 또는 3인;화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염.
- 제 1 항에 있어서,A는 -시아노, -COR1, -C=NOHR2 또는 -헤테로아릴이며;R1는 -NR3R4, -NR3OR4 또는 -OR5 이며;R2는 -NR3R4 이며;R3 및 R4는 각각 독립적으로 -수소, -C1-6 알킬 또는 -헤테로아릴이며;R5는 -C5-20 알킬, -(CH2)n-O-(CH2)-O-CH3, -(CH2)n-OCOO-CH3, -(CH)CH3-OCOO-C3-6 사이클로알킬 또는 -(CH2)n-헤테로아릴이며;B는 -(CH2)n-R6 이며;R6는 -C1-6 알콕시, 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴이고 {여기서, 상기 4-6원 헤테로시클로알킬, -아릴 또는 -헤테로아릴의 하나 이상의 H는 -C1-6 알킬 또는 -할로겐으로 치환될 수 있음};n은 1 또는 2인;화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염.
- 제 1 항에 있어서,하기 화학식들로 이루어진 군으로부터 선택된 화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염:1) 트리데실 (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세테이트;2) (5-메틸-2-옥소-1,3-디옥솔-4-일)메틸 (2S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-(옥세탄-2-일메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세테이트;3) (5-메틸-2-옥소-1,3-디옥솔-4-일)메틸 (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-1-(2-메톡시에틸)-2,3,6-트리메틸-1H-피롤로[2,3-b]피리딘-5-일)아세테이트;4) (5-메틸-2-옥소-1,3-디옥솔-4-일)메틸 (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세테이트;5) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세트아미드;6) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세토니트릴;7) (S)-5-(터트-부톡시(1H-테트라졸-5-일)메틸)-4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘;8) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)-N-메틸아세트아미드;9) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)-N-메톡시아세트아미드;10) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)-N-메톡시-N-메틸아세트아미드;11) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)-N-히드록시아세트아미드;12) (S,Z)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤[2,3-b]피리딘-5-일)-N'-히드록시아세트이미다마이드;13) (S)-3-(터트-부톡시(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸l-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)메틸)-5-메틸-1,2,4-옥사디아졸;14) (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)-N-(2H-테트라졸-5-일)아세트아미드;15) ((메톡시카보닐)옥시)메틸 (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세테이트;16) 2-(2-메톡시에톡시)에틸 (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-피라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세테이트;17) 1-(((시클로헥실옥시)카보닐)옥시)에틸 (2S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-2,3,6-트리메틸-1-((1-메틸-1H-파라졸-4-일)메틸)-1H-피롤로[2,3-b]피리딘-5-일)아세테이트; 및18) (5-메틸-2-옥소-1,3-디옥솔-4-일)메틸 (S)-2-(터트-부톡시)-2-(4-(4-클로로페닐)-1-(3,4-디플루오로벤질)-2,3,6-트리메틸-1H-피롤로[2,3-b]피리딘-5-일)아세테이트인 화합물, 이의 라세미체, 입체이성질체 또는 이의 약학적으로 허용 가능한 염.
- 제 1 항 내지 제 5 항 중 어느 한 항의 화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 항바이러스용 약학적 조성물.
- 제 6 항에 있어서,항인간면역결핍바이러스(HIV)용 약학적 조성물.
- 제 1 항 내지 제 5 항 중 어느 한 항의 화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이의 약학적으로 허용 가능한 염의 치료학적으로 유효한 양의 투여를 포함하는 바이러스 감염 치료방법.
- 바이러스 감염 치료용 약제의 제조를 위한, 제 1 항 내지 제 5 항 중 어느 한 항의 화학식 I로 표시되는 화합물, 이의 라세미체, 이의 입체이성질체 또는 이들의 약학적으로 허용가능한 염의 용도.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023512003A JP2023538582A (ja) | 2020-08-20 | 2021-08-20 | ピロロピリジン誘導体及びそれらの用途 |
BR112023003144A BR112023003144A2 (pt) | 2020-08-20 | 2021-08-20 | Derivado de pirrolopiridina e uso do mesmo |
AU2021327616A AU2021327616B2 (en) | 2020-08-20 | 2021-08-20 | Pyrrolopyridine derivative and use thereof |
US18/021,930 US20230373994A1 (en) | 2020-08-20 | 2021-08-20 | Pyrrolopyridine derivative and use thereof |
EP21858638.6A EP4201405A1 (en) | 2020-08-20 | 2021-08-20 | Pyrrolopyridine derivative and use thereof |
CN202180050833.7A CN115916345A (zh) | 2020-08-20 | 2021-08-20 | 吡咯并吡啶衍生物及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200104758A KR20220023187A (ko) | 2020-08-20 | 2020-08-20 | 피롤로피리딘 유도체 및 이들의 용도 |
KR10-2020-0104758 | 2020-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022039551A1 true WO2022039551A1 (ko) | 2022-02-24 |
Family
ID=80323119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/011116 WO2022039551A1 (ko) | 2020-08-20 | 2021-08-20 | 피롤로피리딘 유도체 및 이들의 용도 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230373994A1 (ko) |
EP (1) | EP4201405A1 (ko) |
JP (1) | JP2023538582A (ko) |
KR (1) | KR20220023187A (ko) |
CN (1) | CN115916345A (ko) |
AU (1) | AU2021327616B2 (ko) |
BR (1) | BR112023003144A2 (ko) |
WO (1) | WO2022039551A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005103003A2 (en) * | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
US20100179139A1 (en) * | 2007-06-01 | 2010-07-15 | Paul Bamborough | Pyrrolopyridine compounds, process for their preparation, and their use as medicaments |
KR20130054211A (ko) * | 2011-11-15 | 2013-05-24 | 한국화학연구원 | 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법 |
KR20150141275A (ko) * | 2014-06-09 | 2015-12-18 | 한국화학연구원 | 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도 |
KR20190141152A (ko) * | 2017-03-24 | 2019-12-23 | 에스티팜 주식회사 | 신규한 피롤로피리딘 유도체, 이의 제조방법 및 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012209373A1 (en) * | 2011-01-24 | 2013-04-11 | Glaxosmithkline Llc | Isoquinoline compounds and methods for treating HIV |
US8609653B2 (en) * | 2011-07-15 | 2013-12-17 | Glaxosmithkline Llc | Azaindole compounds and methods for treating HIV |
-
2020
- 2020-08-20 KR KR1020200104758A patent/KR20220023187A/ko unknown
-
2021
- 2021-08-20 AU AU2021327616A patent/AU2021327616B2/en active Active
- 2021-08-20 WO PCT/KR2021/011116 patent/WO2022039551A1/ko unknown
- 2021-08-20 JP JP2023512003A patent/JP2023538582A/ja active Pending
- 2021-08-20 EP EP21858638.6A patent/EP4201405A1/en active Pending
- 2021-08-20 CN CN202180050833.7A patent/CN115916345A/zh active Pending
- 2021-08-20 US US18/021,930 patent/US20230373994A1/en active Pending
- 2021-08-20 BR BR112023003144A patent/BR112023003144A2/pt unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005103003A2 (en) * | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
US20100179139A1 (en) * | 2007-06-01 | 2010-07-15 | Paul Bamborough | Pyrrolopyridine compounds, process for their preparation, and their use as medicaments |
KR20130054211A (ko) * | 2011-11-15 | 2013-05-24 | 한국화학연구원 | 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법 |
KR20150141275A (ko) * | 2014-06-09 | 2015-12-18 | 한국화학연구원 | 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도 |
KR20190141152A (ko) * | 2017-03-24 | 2019-12-23 | 에스티팜 주식회사 | 신규한 피롤로피리딘 유도체, 이의 제조방법 및 용도 |
Non-Patent Citations (1)
Title |
---|
FRAUKE CHRISTZEGER DEBYSER, NATURE CHEMICAL BIOLOGY, vol. 6, 2010, pages 442 - 448 |
Also Published As
Publication number | Publication date |
---|---|
CN115916345A (zh) | 2023-04-04 |
KR20220023187A (ko) | 2022-03-02 |
EP4201405A1 (en) | 2023-06-28 |
AU2021327616A1 (en) | 2023-03-02 |
JP2023538582A (ja) | 2023-09-08 |
US20230373994A1 (en) | 2023-11-23 |
BR112023003144A2 (pt) | 2023-04-04 |
AU2021327616B2 (en) | 2024-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6774134B2 (en) | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | |
AU696390B2 (en) | Quinolones and their therapeutic use | |
US20030232860A1 (en) | Medicine comprising dicyanopyridine derivative | |
WO2000004900A1 (en) | Substituted benzimidazole antiviral agents | |
WO2020256477A1 (ko) | 암 세포 성장을 억제하는 피리미딘 유도체 및 이의 의약 용도 | |
WO2011159129A2 (ko) | 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 | |
WO2018174320A1 (ko) | 신규한 피롤로피리딘 유도체, 이의 제조방법 및 용도 | |
JPH04217956A (ja) | 新規デオキシノジリマイシン誘導体、その製造方法及び薬剤としてのそれらの使用 | |
WO2017209322A1 (ko) | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
WO2022039551A1 (ko) | 피롤로피리딘 유도체 및 이들의 용도 | |
EP0300725B1 (en) | Tetrahydroisoquinolin-2-yl derivatives as thromboxane A2 antagonists | |
WO2004096774A1 (en) | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents | |
RU2815649C1 (ru) | Пирролопиридиновое производное и его применение | |
WO2021112620A9 (ko) | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 | |
WO2020040343A1 (en) | Isoxazole derivatives and preparation process thereof | |
WO2022086085A1 (ko) | 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 | |
WO2023096313A1 (ko) | 플라보논 유도체 화합물 및 이의 섬유증을 치료 또는 완화하기 위한 의약 용도 | |
WO2023146244A1 (ko) | 벤조다이옥세인 유도체 화합물 및 이의 의약 용도 | |
WO2020213970A1 (ko) | 캐스파제 저해제의 프로드럭 | |
WO2023113458A1 (en) | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof | |
WO2024101764A1 (ko) | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 | |
WO2012050380A2 (en) | Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof | |
WO2023090947A1 (ko) | 코로나바이러스 감염 질환의 예방 또는 치료용 약제학적 조성물 | |
WO2021085991A1 (ko) | Fxr 활성효과를 가지는 시나믹아마이드 유도체, 이를 유효성분으로 함유하는 약학적 조성물 및 이의 제조방법 | |
WO2022145923A1 (ko) | 피페론구민계 화합물을 유효성분으로 포함하는 바이러스 감염증의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21858638 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023512003 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023003144 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021327616 Country of ref document: AU Date of ref document: 20210820 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021858638 Country of ref document: EP Effective date: 20230320 |
|
ENP | Entry into the national phase |
Ref document number: 112023003144 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230217 |